Axon Enterprise (NASDAQ:AXON) Downgraded by Northcoast Research to “Neutral”

Northcoast Research downgraded shares of Axon Enterprise (NASDAQ:AXON) from a buy rating to a neutral rating in a research report report published on Wednesday, Marketbeat.com reports.

A number of other equities analysts have also recently weighed in on AXON. Northland Securities increased their price target on Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. Needham & Company LLC increased their target price on shares of Axon Enterprise from $525.00 to $600.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. JMP Securities boosted their price target on shares of Axon Enterprise from $610.00 to $725.00 and gave the company a “market outperform” rating in a research note on Tuesday, February 4th. The Goldman Sachs Group lifted their target price on shares of Axon Enterprise from $500.00 to $700.00 and gave the company a “buy” rating in a report on Monday, January 27th. Finally, Robert W. Baird upped their price target on Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research note on Friday, December 6th. Two research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $542.15.

Axon Enterprise Trading Down 16.4 %

AXON opened at $593.42 on Wednesday. The stock has a market capitalization of $45.25 billion, a PE ratio of 153.34, a P/E/G ratio of 6.85 and a beta of 1.05. Axon Enterprise has a one year low of $260.27 and a one year high of $715.99. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. The business’s 50 day moving average price is $624.50 and its 200 day moving average price is $515.36.

Insider Buying and Selling

In other news, insider Jeffrey C. Kunins sold 2,304 shares of the company’s stock in a transaction dated Tuesday, December 3rd. The stock was sold at an average price of $654.79, for a total transaction of $1,508,636.16. Following the completion of the transaction, the insider now directly owns 128,542 shares of the company’s stock, valued at approximately $84,168,016.18. This represents a 1.76 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Caitlin Elizabeth Kalinowski sold 450 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $604.07, for a total value of $271,831.50. Following the sale, the director now directly owns 6,929 shares in the company, valued at $4,185,601.03. This trade represents a 6.10 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 8,711 shares of company stock worth $5,631,561. Company insiders own 5.70% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Asset Dedication LLC boosted its holdings in shares of Axon Enterprise by 11.3% in the 4th quarter. Asset Dedication LLC now owns 178 shares of the biotechnology company’s stock valued at $106,000 after buying an additional 18 shares in the last quarter. Bleakley Financial Group LLC boosted its stake in Axon Enterprise by 1.3% in the fourth quarter. Bleakley Financial Group LLC now owns 1,527 shares of the biotechnology company’s stock valued at $908,000 after acquiring an additional 20 shares in the last quarter. Venturi Wealth Management LLC boosted its stake in Axon Enterprise by 2.7% in the fourth quarter. Venturi Wealth Management LLC now owns 802 shares of the biotechnology company’s stock valued at $477,000 after acquiring an additional 21 shares in the last quarter. Insigneo Advisory Services LLC grew its holdings in shares of Axon Enterprise by 1.4% during the third quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock worth $627,000 after purchasing an additional 22 shares during the last quarter. Finally, Beacon Pointe Advisors LLC increased its position in shares of Axon Enterprise by 2.6% during the fourth quarter. Beacon Pointe Advisors LLC now owns 864 shares of the biotechnology company’s stock worth $513,000 after purchasing an additional 22 shares in the last quarter. 79.08% of the stock is owned by institutional investors and hedge funds.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.